參 考 文 獻
民國九十年台灣地區主要死亡原因。行政院衛生署。
民國九十年台灣地區癌症主要死亡原因。行政院衛生署。
賴羿如、項千芸、侯庭鏞。肝細胞轉形之分子機制及分子療程之探討。中國醫藥學院醫學研究所 碩士論文(2000)。
Adlercreutz, H, 1990. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand. Clin. Lab. Invest. Suppl. 201, 3-23.
Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R.J., Rahmsdorf, H.J., Jonat, C., Herrlich, P., and Karin, M. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49: 729-739.
Angel, P., and Karin, M. 1991. The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim. Biophy. Acta. 1072: 129-157.
Befeler, A.S. and Bisceglie, A.M.D., 2002. Hepatocellular carcinoma: diagnosis and treatment.
Gastroenterology 122:1609-1619
Bernstein, L.R., and Colburn, N.H. 1989. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244: 566-569.
Birt, DF, Mitchell, D, Gold, B, Pour, P, Pinch, HC, et al.1997. Inhibition of ultraviolet light-induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res. 17, 85-91.
Bismuth, H., Chiche, L., Castaing, D. 1995. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J. Surg.19:35–41.
Bruce A . et al., 2002, Molecular biology of the cell, 4th edition. pp 983-1026.
Buja, L.M., Ferrans, V.J., Mayers, R.J., Robert, W.C., Henderson, E.S., 1973. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 32, 771-/778.
Caitagirone, S, Rossi, C, Poggi, A., Ranelletti, F.O., Natali, P.G. et al. 2000. Flavonoids apigenin and quercitin inhibit melanoma growth and metastatic potential. Int. J. Cancer. 87, 595-600.
Carroll, K.K., Guthrie, N., So, F.V., and Chambers, A.F. 1998. Anticancer properties of flavonoids, with emphasis on citrus flavonoids. Flavonoids in health and disease. pp 437-446.
Chaumontet, C., Bex, V., Gaillard-Sanchez, I., Seillan-Heberden, C., Suschete, M. et al. 1994.
Apigenin and tangeretin enhance gap junction intercellular communication in rat liver epithelial cells.
Carcinogenesis 15, 2325-2330.
Cody, V. , Middleton, E., Harborne, J.B., and Beretz, A. 1988. Plant flavonoids in biology and Medicine II: Biochemical, Cellular and Medicinal Properties. Alan R. Liss Inc., New York.
Diplock, A.T., Charleux, J.L., Crfozier-Willi, G., Kok, F.J., Rice-Evans, C., Roberfroid, M., Stahl, W., Vina-Ribes, J., 1998. Functional food science and defence against reactive oxygen species. Br. J.
Nutr. 80, 77-/112.
Domann, F.E., Levy, J.P., Birrer, M.J., and Bowden, G.T. 1994. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell
Growth Differ. 5: 9-16.
Dong, Z., Birrer, M.J., Watts, R.G., Matrisian, L.M., and Colburn, N.H. 1994. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc.
Natl. Acad. Sci. 91: 609-613.
Elledge S.J., and Harper J.W. 1994. Cdk inhibitors: on the threshold of checkpoints and development.
Curr. Opin. Cell Biol. 6: 847-852.
Fornari, F.A., Randolph, J.K., Yalowich, J.C., Ritke, M.K., Gewirtz, D.A. 1994. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumour cells. Mol. Pharmacol. 45, 649-/656.
Gabor, M. 1979. Anti-inflammatory substances of plant origin, in handbook of experimental pharmacology: Anti-inflammatory drugs. pp698-739. Spinger-Verlag, New York.
Gabor, M. 1986. The pharmacology of benzopyrone derivatives and related compounds, Akademiai Kiad, Budapest.
Gewirtz, D.A. 1999. A Critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-/741.
Goldberg Y, Nassif II, Pittas A, Tsai L.L., Dynlacht B.D., Rigas B., and Shiff S.J. 1996. the anti-prolferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alternations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12: 893-901.
Graves, P.R., Yu, L., Schwarz, J.K., Gales, J., Sausville, E.A., O’Connor, P.M., and Piwnica-Worms, H.
2000. The chk1 protein kinase and the cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem., 275: 5600-5605.
Gupta, S., Barrett, T., Whitmarsh, A.J., Cavanagh, J., Sluss, H.K., Derijard, B., and Davis, R.J. 1996.
Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:
2760-2770.
Gupta, S., Campbell, D., Dérijard, B., and Davis, R.J. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393.
Halazonetis, T.D., Georgopoulos, K., Greenberg, M.E. and Leder, P. 1988. C-jun dimerizes with itself and c-fos forming complexes of different DNA binding abilities. Cell 55: 917-924.
Harborne, J.B. 1988a. The flavonoids: Advances in Research Since 1986. Chapman & Hall, New York Harborne, J.B. 1988b. Flavonoids in the environment: Structure-activity relationships, in Plant
flavonoids in Biology and Medicine II: Biochemical Cellular and Medicinal Properties. pp 17-28, Alan R. Liss, Inc: New York.
Harbury, P.B., Zhang, T., Kim, P.S., and Alber, T. 1993. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262: 1401-1407.
Harrison’s Principles of Internal Medicine, 14th Ed. pp 579-580
Hartwell, L. H., and Kastan, M. B. 1994. Cell cycle control and cancer. Science, 266:1821-1828.
Havsteen, B. 1984. Flavonoids: A class of natural products of high pharmacological potency. Biochem.
Pharmacol. 32: 1141-1148.
Herschman, H.R. 1991. Primary response genes induced by growth factors and tumor promoters. Ann.
Rev. Biochem. 60: 281-319.
Ichinose, Y., Takanashi, N., Yano, T., 1995. A phase III trial of oral tegafur and uracil p lus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 75, 2677-2680.
Jia, S.S., Ma, C.M., Li, Y.H., Hao, J.H. 1992. Glycosides of phenolic acid and flavonoids from the leaves of Glycyrrhiza uralensis Ficsh. Yao Xue Xue Bao. 27(6):441-4.
Jochum, W., Passegue, E., Wagner, E.F. 2001. AP-1 in mouse development and tumorigenesis.
Oncogene 30;20(19):2401-12.
Kaufmann, W.K., Levedakuo, E.N., Grady, H.L., Paules, R.S., and Stein, G.H. 1995. attenuation of G2 checkpoint function precedes human cell immortalization. Cancer Res. 55: 7-11,.
Koo, H., Rosalen, P.L., Cury, J.A., Park, Y.K., Bowen, W.H. 2002. Effects of compounds found in propolis on Streptococcus mutans growth and on glucosyltransferase activity. Antimicrob. Agents Chemother. 46(5):1302-9.
Kuo, M.L., Lee, K.C., and Lin, J.K. 1992. Genotoxicities of nitropyrenes and their modulation by apigenin, tannic acid, ellagic acid and indole-3-carbinol in the Salmonella and CHO systems. Mutat.
Res. 270, 87-95.
Lamb, R.F., Hennigan, R.F., Turnbull, K., Katsanakis, K.D., MacKenzie, E.D., Birnie, G.D., and Ozanne, B.W. 1997. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 17: 963-976.
Landschulz, W.H., Johnson, P.F., and McKnight, S.L. 1988. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240: 1759-1764.
Lefrak, E.A., Pitha, J., Rosenheim, S., Gottleib, J.A., 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-/314.
Lepley, D.M., Li, B., Birt, D.F. and Pelling, J.C.. 1996. The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis 17: 2367-2375,.
Li, J.J., Rhim, J.S., Schlegel, R., Vousden, K.H., and Colburn, N.H. 1998. Expression of dominant negative Jun inhibits elevated AP-1 and NF -kappa B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 16: 2711-2721.
Mac Vean, M., Weinberg, W.C., and Pelling, J.C. 2002. Ap21waf1-independent pathway for inhibitory phosphorylation of cyclin-dependent kinase p34cdc2 and concomitant G2-M arrest by the chemopreventive flavonoid apigenin. Mol. Carcinogenesis 33: 36-43,.
Mac Vean, M, Xiao, H, Isobe, K, and Pelling, J.C. 2000. increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis 21, 633-639.
Middleton, E. 1984. The flavonoids. Trends. Pharmacol. Sci. 277, 375-381.
Middleton, E., and Kandaswami, C. 1993. The impact of plant flavonoids on mammalian biology:
Implications for immunity, inflammation and cancer, in The Flavonoids: Advances in Research Science 1986 (Harborne IR ed) pp 619-645. Chapman and Hall, London.
Moragoda, L., Jaszewski, R., and Majumdar, A.P. 2001. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21:873-878.
O'Neil, K.T., Hoess, R.H., and DeGrado, W.F. 1990. Design of DNA-binding peptides based on the leucine zipper motif. Science 249: 774-778.
Sadzuka, Y., Mochizuki, E., Takino, Y., 1995. Mechanism of caffeine modulation of the antitumor activity of adriamycin. Toxicol. Lett. 75, 35-49.
Sato, F., Matsukawa, Y., Matsumoto, K., Nishino, H., and Sakai, T. 1994. Apigenin induces morphological differentiation and G2-M arrest in rat neural cells. Biochem. and Biophys. Res. Com.
204: 578-584.
Shapiro, G.I., Koestner, D.A., Matranga, C.B., and Rollins, B.J. 1999. Flavopiridol induces cell cycle arrest and P53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. 5:
2925-2938,.
Sheer C.J. 1996. cancer cell cycle. Science 274: 1672-1677.
Shuman, J.D., Vinson, C.R., and McKnight, S.L. 1990. Evidence of changes in protease sensitivity and subunit exchange rate on DNA binding by C/EBP. Science 249: 771-774.
Singal, P.K., Deally, C.M.R., Weinberg, L.E., 1987. Subcellular effects of adriamycin in the heart: a concise review. J. Mol. Cell. Cardiol. 19, 817-/828.
Singal, P.K., Iliskovic, N., 1998. Adriamycin cardiomyopathy. N. Engl. J. Med. 339, 900-/905.
Singal, P.K., Li, T., Kumar, D., Danelisen, I., Iliskovic, N., 2000. Adriamycin-induced heart-failure:
mechanism and modulation. Mol. Cell. Biochem. 207, 77-/85.
Southern, P.J., and Berg, P. 1982. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet. 1: 327-341.
Stochmal, A, Piacente, S, Pizza, C, De Riccardis , F, Leitz, R, Oleszek, W. 2001. Alfalfa (Medicago sativa L.) flavonoids. 1. Apigenin and luteolin glycosides from aerial parts. J. Agric. Food Chem.
49(2):753-8.
Taylor, I.C., and Kingston, R.E. 1990. Factor substitution in a human HSP70 gene promoter:
TATA-dependent and TATA -independent interactions. Mol. Cell Bio. 10: 165-175.
Taylor, W.R., and Stark, G.R. 2001. Regulation of the G2-M transition by p53. Oncogene, 20:
1803-1815.
Tyagi, A.K., Singh, R.P., Agarwal, C., Chan, D.C.F., and Agarwal, R. 2002. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer Res. 8:3512-3519.
Van Acker, S.A.B.E., Kramer, K., Grimbergen, J.A., Van der Berg, D.J., Van der Vijgh, W.J.F., Bast, A., 1995. Monohydroxyethylrutoside a protector against chronic doxorubicin-induced cardiotoxicity.
Br. J. Pharmacol. 115, 1260-1264.
Van Acker, S.A.B.E., Boven, E., Juiper, K., Van der Berg, D.J., Grimbergen, J.A., Kramer, K., Bast, A., Van der Vijgh, W.J.F., 1997. Monohydroxyethylrutoside is a dose dependent cardioprotective agent and does not affect the antitumor activity of doxorubicin. Clin. Cancer Res. 3, 1747-1754.
Vinson, C.R., Sigler, P.B., and McKnight, S.L. 1989. Scissors -grip model for DNA recognition by a family of leucine zipper proteins. Science 246: 911-916.
Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Von Hoff, A.L., Rozwncweig, M., and Muggia, F.
M.: Risk factors for doxorubicin -induced congestive heart failure. Ann. Intern. Med. 91: 710-717, 1979.
Wang, C, and Kurzer, M.S. 1997. Phytoestrogen concentration determines effects on DNA synthesis in
human breast cancer cells. Nutr. Cancer 28, 236-247.
Wang, I.K., Lin-Shiau, S.Y., and Lin, J.K. 1999. induction of apoptosis by apigenin and related flavonoids through cytochrome C release and activation of caspas e-9 and caspase-3 in leukemia HL-60 cells. Eur. J. Cancer 35, 1517-1525.
Wang, W, Heideman, L, Chung, C.S., Pelling, J.C., Koehler, K.J. et al. 2000. Cell cycle arrest at G2-M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol. Carcinog. 28, 102-110.
Wang, W., Heideman, L., Chung, C.S., Pelling, J.C., Koehler, K.J. and Birt, D.F. 2000. Cell-cycle arrest at G2-M and growth inhibition by apigenin in human colon carcinoma cell line. Mol. Carcinog.
28:102-110.
Yin, F., Giuliano, A.E., Law, R.E., and Van Herle, A.J. 2001. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 21: 413-420.
